In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients—Removal of Excess Glucose (EMPA-REG OUTCOME) trial, the difference between empagliflozin, a highly selective SGLT2 inhibitor (2500-fold compared to SGLT1), and placebo was driven by a significant reduction in hospitalization for heart failure, with no significant between-group difference in the risk of myocardial infarction or stroke [10]. Here, SLC5A2 is linked to heart failure.